Clinical Data Planning to Exit Genetic Testing Business to Fully Focus on Drug Development | GenomeWeb

By Turna Ray

Clinical Data is looking to move entirely away from its genetic-testing and biomarker-development business and become a pure-play drug developer.

In documents filed with the US Securities and Exchange Commission this week, Clinical Data, which at one point aimed to become a personalized medicine company, said that it is now "considering the sale of its genetic testing and biomarker development business."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.